Hyperfractionated-accelerated or conventionally fractionated radiotherapy for early glottic cancer

Haugen, Hedda; Johansson, Karl-Axel; Mercke, Claes

doi:10.1016/s0360-3016(01)01812-0

Cited by 21 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They comprise as many as 33% of the study population. The most common causes of death were second malignancies (mostly lung), cardiovascular disease and pneumonia, which is almost identical to what we have found for patients with early laryngeal cancer [1]. Despite LC and LRC, patients with laryngeal cancer appear to have a high risk of dying of intercurrent diseases where one common risk factor is likely to be cigarette smoking.…”

Section: Discussionsupporting

confidence: 83%

“…Our LC and LRC results for advanced laryngeal cancer are clearly worse, compared to the LC and LRC for early glottic cancer in our institution also treated with accelerated RT [1]. When compared to the results for advanced laryngeal cancer described in the literature, both for RT and surgery, our results for T3 are in line with those of others and those for T4 are well comparable and perhaps among the better [3,7 Á/14].…”

Section: Discussionsupporting

confidence: 79%

“…This strategy yields satisfactory results with respect to tumor control, survival and laryngeal function in most patients [1]. For T2 tumors accelerated fractionation of RT has given similar local control (LC) as for conventionally fractionated T1 tumors, suggesting the importance of a short treatment time on RT results even for a low tumor stage [1]-a finding later supported by Garden et al [2].…”

mentioning

confidence: 76%

“…With information from patients' records and the Swedish national statistical register, as described previously [1], we were able to establish the cause of death in all but one case. The most common cause of death was a second malignancy.…”

Section: Figuresmentioning

confidence: 99%

See 3 more Smart Citations

Accelerated radiotherapy for advanced laryngeal cancer

et al. 2005

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 79%

mentioning

confidence: 76%

Section: Figuresmentioning

confidence: 99%

See 2 more Smart Citations

Accelerated radiotherapy for advanced laryngeal cancer

et al. 2005

Self Cite

View full text Add to dashboard Cite

“…The main rationale for this strategy is that radiotherapy offers a possibility to preserve laryngeal function. For early laryngeal cancer (glottic T 1 T 2 N 0 M 0 tumors) treated with radiotherapy in our institution, we have reported a 5-year locoregional control of 85% (1). The corresponding results for advanced laryngeal cancer are 49% for T 3 and 75% for T 4 tumors, respectively, with a larynx preservation rate for the surviving patients of 91% (2).…”

Section: Introductionmentioning

confidence: 82%

Preradiotherapy Hemoglobin Level but not Microvessel Density Predicts Locoregional Control and Survival in Laryngeal Cancer Treated with Primary Radical Radiotherapy

Haugen¹,

Magnusson²,

Svensson

et al. 2004

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the roles of preradiotherapy hemoglobin level and microvessel density (MVD) as predictive factors for tumor control and survival in patients with laryngeal cancer treated with primary radiotherapy.Experimental Design: Two hundred and fourteen patients with stage I-IV laryngeal cancer were included in the analysis. Patients were treated with once daily fractionated radiotherapy over 6.5 weeks or twice daily fractionated radiotherapy over 4.5 weeks up to total doses of 62 to 68 Gy. Preradiotherapy hemoglobin levels were obtained from patient journals, and pretreatment tumor biopsies were stained with CD34 antibody for the counting of microvessels. The prognostic implication of preradiotherapy hemoglobin level and MVD on tumor control and survival was tested.Results: Five-year locoregional control probability was 88.9% for patients with preradiotherapy hemoglobin levels >137.5 g/L (median) and 64.4% for patients with preradiotherapy hemoglobin levels <137.5 g/L (P ‫؍‬ 0.01). The corresponding figures for disease-free survival were 87.8 and 62.8% (P ‫؍‬ 0.007), respectively, and for overall survival 58.1 and 40.3% (P < 0.001), respectively.In multivariate analysis, tumor stage and preradiotherapy hemoglobin level were significant prognostic factors for locoregional control and disease-free survival, whereas tumor stage, preradiotherapy hemoglobin-level, gender, and age were significant prognostic factors for overall survival. No correlation was found between MVD and tumor control and survival.Conclusion: Preradiotherapy hemoglobin level, but not MVD, predicts locoregional control and survival in patients with laryngeal cancer treated with radiotherapy.

show abstract